In October, due to demand from existing healthcare partners, CTS began testing blood donors for antibody to Babesia microti under an Investigational New Drug exemption as a release test.
CTS Research Consortium was established to further CTS’s leadership in infectious disease research....
Continue to meet or exceed healthcare partners’ expectations by providing on-time test results appr...
CTS embraces a company-wide operational excellence initiative designed to change the culture to enha...
In August, the CTS Tampa lab transitioned to the same laboratory information systems (LIS) as the Da...
In 2016, CTS tested more source plasma samples (4.9 million) than blood donor samples (4.5 million).
Transitioned all 5 CTS labs from an investigational new drug (IND) to a licensed pooled Babesia test...